AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2126633 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Gy
Number of subjects: 550
Study 2126633 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 Gy
Number of subjects: 550
Study 2126633 — intervention group
Group type: EXPERIMENTAL
Intervention: 20/20.4 Gy
Number of subjects: 550
Study 2126633 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 Gy
Number of subjects: 550
Study 2126633 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 Gy
Number of subjects: 550
Study 7436690 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine hydrochloride
Number of subjects: 22
Study 7436690 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline hydrochloride
Number of subjects: 22
Study 7436690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31855924 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot massage
Number of subjects: 196
Study 31855924 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand massage
Number of subjects: 196
Study 31855924 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 196
Study 30153580 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorus (500 mg) with a high-carbohydrate meal
Number of subjects: 15
Study 30153580 — intervention group
Group type: COMPARATOR
Intervention: Placebo with a high-carbohydrate meal
Number of subjects: 15
Study 28500089 — intervention group
Group type: EXPERIMENTAL
Intervention: Manchester Acute Coronary Syndromes (MACS) decision rule
Number of subjects: 10
Study 28500089 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 10
Study 26059086 — intervention group
Group type: EXPERIMENTAL
Intervention: InCARE intervention for informal caregivers
Number of subjects: 198
Study 22405094 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gauze pad
Number of subjects: 89
Study 22405094 — intervention group
Group type: COMPARATOR
Intervention: Neutral vehicle
Number of subjects: 89
Study 21098520 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 0
Study 21098520 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen plus codeine
Number of subjects: 0
Study 21098520 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen plus midazolam
Number of subjects: 0
Study 21098520 — intervention group
Group type: COMPARATOR
Intervention: Control group (Acetaminophen alone)
Number of subjects: 0
Study 19196729 — intervention group
Group type: EXPERIMENTAL
Intervention: SubRPE (5000 m at a constant rating of perceived exertion RPE 15-Hard)
Number of subjects: 9
Study 19196729 — intervention group
Group type: COMPARATOR
Intervention: SubEXT (5000 m at an enforced constant pace equivalent to the mean power output of SubRPE)
Number of subjects: 9
Study 19196729 — intervention group
Group type: EXPERIMENTAL
Intervention: MaxTT (maximal condition included for randomization)
Number of subjects: 9
Study 16979855 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood sampling from the forearm using the Free Style device
Number of subjects: 60
Study 16979855 — intervention group
Group type: COMPARATOR
Intervention: Conventional blood sampling from the heel using a lancet
Number of subjects: 60
Study 14998609 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery stenting
Number of subjects: 611
Study 14998609 — intervention group
Group type: COMPARATOR
Intervention: PTCA (balloon angioplasty)
Number of subjects: 611
Study 9418710 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimplantation genetic diagnosis for aneuploidy
Number of subjects: 28
Study 9418710 — intervention group
Group type: COMPARATOR
Intervention: Assisted zona hatching
Number of subjects: 28
Study 8494378 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 9
Study 8494378 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 9
Study 3806894 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal human diploid cell rabies vaccine (ID HDCV)
Number of subjects: 124
Study 29241421 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (220 mg zinc sulfate capsules every 72 hours for 1 month)
Number of subjects: 54
Study 29241421 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 54
Study 29241421 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 54
Study 25846071 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum BB536 (BB536) supplementation
Number of subjects: 300
Study 25846071 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 300
Study 24937077 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking prevention program 'ohnekippe'
Number of subjects: 1427
Study 24937077 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1427
Study 24937077 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified smoking prevention program 'ohnekippe'
Number of subjects: 1427
Study 24937077 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall smoking prevalence in the catchment area
Number of subjects: 1427
Study 22752567 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus dexamethasone
Number of subjects: 704
Study 22752567 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus dexamethasone
Number of subjects: 704
Study 20705223 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain (approximately 4 kg) over 8 weeks
Number of subjects: 43
Study 20705223 — intervention group
Group type: COMPARATOR
Intervention: Weight maintenance (no weight gain)
Number of subjects: 43
Study 20705223 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss after fat gain
Number of subjects: 43
Study 20705223 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral fat gain
Number of subjects: 43
Study 20705223 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous fat gain
Number of subjects: 43
Study 18644682 — intervention group
Group type: EXPERIMENTAL
Intervention: Anonymous questionnaire + BPL
Number of subjects: 801
Study 18644682 — intervention group
Group type: EXPERIMENTAL
Intervention: Named questionnaire + BPL
Number of subjects: 801
Study 18644682 — intervention group
Group type: COMPARATOR
Intervention: Anonymous questionnaire without BPL
Number of subjects: 801
Study 18644682 — intervention group
Group type: COMPARATOR
Intervention: Named questionnaire without BPL
Number of subjects: 801
Study 15958805 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of MLN02 per kilogram
Number of subjects: 181
Study 15958805 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg of MLN02 per kilogram
Number of subjects: 181
Study 15958805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 12210871 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Parkinson's Disease Rating Scale (UPDRS)
Number of subjects: 400
Study 12210871 — intervention group
Group type: EXPERIMENTAL
Intervention: Derived symptom-based scales
Number of subjects: 400
Study 12210871 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing interval within 14 days
Number of subjects: 400
Study 10325259 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous oestradiol 0.1 mg/day from day 10 after the LH surge until day 4 of the following cycle
Number of subjects: 6
Study 10325259 — intervention group
Group type: COMPARATOR
Intervention: Control cycle
Number of subjects: 6
Study 10325259 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous oestradiol 0.1 mg/day
Number of subjects: 6
Study 10325259 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 6
Study 7758304 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbopol gel with 10% CaNa2-EDTA
Number of subjects: 21
Study 7758304 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbopol gel without CaNa2-EDTA
Number of subjects: 21
Study 7758304 — intervention group
Group type: COMPARATOR
Intervention: Nickel alloy without barrier gel
Number of subjects: 21
Study 1955506 — intervention group
Group type: EXPERIMENTAL
Intervention: Al(OH)3
Number of subjects: 14
Study 7141605 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dietary salt restriction
Number of subjects: 25
Study 6390659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen 0.5 mg X 2 daily
Number of subjects: 260
Study 6390659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen 1 mg X 2 daily
Number of subjects: 260
Study 6390659 — intervention group
Group type: COMPARATOR
Intervention: Clemastine fumarate 1.34 mg X 2 daily
Number of subjects: 260
Study 6390659 — intervention group
Group type: COMPARATOR
Intervention: Placebo for ketotifen
Number of subjects: 260
Study 6390659 — intervention group
Group type: COMPARATOR
Intervention: Placebo for clemastine
Number of subjects: 260
Study 29775083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg IV every 8 h plus enteral nutrition (EN)
Number of subjects: 2
Study 29775083 — intervention group
Group type: COMPARATOR
Intervention: Enteral nutrition (EN) alone
Number of subjects: 2
Study 29775083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg IV every 8 h plus EN
Number of subjects: 2
Study 27107849 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol cessation
Number of subjects: 22
Study 27107849 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 22
Study 24140383 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (300,000 IU)
Number of subjects: 50
Study 24140383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 22669346 — intervention group
Group type: EXPERIMENTAL
Intervention: FM algorithm
Number of subjects: 48
Study 22669346 — intervention group
Group type: COMPARATOR
Intervention: VA algorithm
Number of subjects: 48
Study 20220044 — intervention group
Group type: EXPERIMENTAL
Intervention: CP‐642,931 (35 mg daily for 7 days)
Number of subjects: 57
Study 18559904 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert radiologists scoring of parametric images
Number of subjects: 21
Study 18559904 — intervention group
Group type: EXPERIMENTAL
Intervention: Novice radiologists scoring of parametric images
Number of subjects: 21
Study 16499109 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 96
Study 16499109 — intervention group
Group type: COMPARATOR
Intervention: Standard anesthesia (Control)
Number of subjects: 96
Study 11998711 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended arterial revascularisation
Number of subjects: 30
Study 10048793 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin
Number of subjects: 12
Study 10048793 — intervention group
Group type: EXPERIMENTAL
Intervention: Galacto‐oligosaccharides (GOS)
Number of subjects: 12
Study 10048793 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructo‐oligosaccharides (FOS)
Number of subjects: 12
Study 10048793 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study 7729018 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG) surgery
Number of subjects: 1484
Study 7729018 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 1484
Study 7729018 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG surgery in patients with normal LV systolic function
Number of subjects: 1484
Study 7729018 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy in patients with normal LV systolic function
Number of subjects: 1484
Study 7729018 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG surgery in patients with normal LV systolic function and right coronary artery stenosis > or = 70%
Number of subjects: 1484
Study 7729018 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy in patients with normal LV systolic function and right coronary artery stenosis > or = 70%
Number of subjects: 1484
Study 2372155 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml of 0.5% bupivacaine injected (1 ml every 10 seconds) for spinal anesthesia in group 1 (n = 16)
Number of subjects: 34
Study 2372155 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml of 0.5% bupivacaine injected for continuous spinal anesthesia in group 2 (n = 18)
Number of subjects: 34
Study 7272174 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 15 mg
Number of subjects: 12
Study 7272174 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 30 mg
Number of subjects: 12
Study 7272174 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 60 mg
Number of subjects: 12
Study 7272174 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 120 mg
Number of subjects: 12
Study 7272174 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) single doses
Number of subjects: 12
Study 7272174 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) chronic dosing
Number of subjects: 12
Study 7272174 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 60 mg single dose
Number of subjects: 12
Study 31723985 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transplantation cyclophosphamide
Number of subjects: 0
Study 31723985 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29340317 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT)
Number of subjects: 20
Study 29340317 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 20
Study 29340317 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SC)
Number of subjects: 20
Study 26743431 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate‐amodiaquine (ASAQ)
Number of subjects: 857
Study 26743431 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether‐lumefantrine (AL)
Number of subjects: 857
Study 23475983 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg EOW
Number of subjects: 229
Study 23475983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 23983351 — intervention group
Group type: EXPERIMENTAL
Intervention: IMUNITI (herbal product with immune-modulating properties)
Number of subjects: 48
Study 23983351 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 48
Study 20919773 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotype threat (ST)
Number of subjects: 0
Study 20919773 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotype threat (ST) during learning modular arithmetic (MA)
Number of subjects: 0
Study 20919773 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 17386059 — intervention group
Group type: EXPERIMENTAL
Intervention: 4:1 ketogenic diet
Number of subjects: 76
Study 17386059 — intervention group
Group type: COMPARATOR
Intervention: 3:1 ketogenic diet
Number of subjects: 76
Study 17386059 — intervention group
Group type: EXPERIMENTAL
Intervention: 4:1 ketogenic diet to 3:1 diet
Number of subjects: 76
Study 17386059 — intervention group
Group type: COMPARATOR
Intervention: 3:1 ketogenic diet to 4:1 diet
Number of subjects: 76
Study 16155693 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planning (FM-SRP)
Number of subjects: 60
Study 16155693 — intervention group
Group type: COMPARATOR
Intervention: Quadrant scaling and root planning (Q-SRP)
Number of subjects: 60
Study 11280495 — intervention group
Group type: COMPARATOR
Intervention: Icodextrin-based PD fluids
Number of subjects: 24
Study 11280495 — intervention group
Group type: COMPARATOR
Intervention: Glucose-based PD fluids
Number of subjects: 24
Study 9374560 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg/kg of RSVIG (RespiGam, MedImmune Inc, Gaithersburg, MD)
Number of subjects: 101
Study 9374560 — intervention group
Group type: COMPARATOR
Intervention: Albumin placebo
Number of subjects: 101
Study 8193609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg once daily (increased to 5.0 mg if necessary)
Number of subjects: 132
Study 8193609 — intervention group
Group type: COMPARATOR
Intervention: Captopril 25 mg twice daily (increased to 50 mg if necessary)
Number of subjects: 132
Study 8193609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril with adjunctive hydrochlorothiazide (12.5 mg once daily)
Number of subjects: 132
Study 8193609 — intervention group
Group type: COMPARATOR
Intervention: Captopril with adjunctive hydrochlorothiazide (12.5 mg once daily)
Number of subjects: 132
Study 3250578 — intervention group
Group type: EXPERIMENTAL
Intervention: RestoreTM Wound Care Dressing (test dressing)
Number of subjects: 0
Study 3250578 — intervention group
Group type: COMPARATOR
Intervention: Duoderm (control dressing)
Number of subjects: 0
Study 29992353 — intervention group
Group type: EXPERIMENTAL
Intervention: REThink intervention
Number of subjects: 165
Study 29992353 — intervention group
Group type: COMPARATOR
Intervention: Rational Emotive Behavior Education condition
Number of subjects: 165
Study 29992353 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 165
Study 28569519 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline plus smoking cessation counseling and prolonged exposure therapy (VARCC + PE)
Number of subjects: 142
Study 28569519 — intervention group
Group type: COMPARATOR
Intervention: Varenicline plus smoking cessation counseling (VARCC)
Number of subjects: 142
Study 28569519 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy (PE)
Number of subjects: 142
Study 26385452 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsened or incomplete ST-segment depression resolution (STD-R)
Number of subjects: 611
Study 26385452 — intervention group
Group type: COMPARATOR
Intervention: Complete ST-segment depression resolution (STD-R)
Number of subjects: 611
Study 23614971 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125%
Number of subjects: 28
Study 23614971 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% and fentanyl 2 μg/mL
Number of subjects: 28
Study 23614971 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.1% plus fentanyl 2 μg/mL and epinephrine 2 μg/mL
Number of subjects: 28
Study 23614971 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 28
Study 21883698 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (0.75 mg)
Number of subjects: 73
Study 21883698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 18188511 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 40
Study 18188511 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 40
Study 18188511 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 40
Study 16769782 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular glucocorticoid treatment with 20 mg triamcinolone hexacetonide (THA) and 24 hour bed rest
Number of subjects: 20
Study 16769782 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular glucocorticoid treatment with 20 mg triamcinolone hexacetonide (THA) and normal activity
Number of subjects: 20
Study 15229016 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical abortion treatment
Number of subjects: 44789
Study 15229016 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment screening methods
Number of subjects: 44789
Study 11466259 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost once daily
Number of subjects: 1256
Study 11466259 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol twice daily
Number of subjects: 1256
Study 9383230 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV) at 6, 8 and 14 months after BMT (early group, n = 23)
Number of subjects: 45
Study 9383230 — intervention group
Group type: COMPARATOR
Intervention: Inactivated poliovirus vaccine (IPV) at 18, 20 and 26 months after BMT (late group, n = 22)
Number of subjects: 45
Study 9383230 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV)
Number of subjects: 45
Study 9383230 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute GVHD
Number of subjects: 45
Study 9383230 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic GVHD
Number of subjects: 45
Study 8256243 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (2 mg/day for five months, then 1 mg/day for three months)
Number of subjects: 15
Study 8256243 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (1.6 mg/day for five months, then 0.8 mg/day for three months)
Number of subjects: 15
Study 8256243 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 15
Study 2863224 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined H1- and H2-receptor antagonists (clemastine and cimetidine)
Number of subjects: 800
Study 2863224 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control group)
Number of subjects: 800
Study 2863224 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prednisolone
Number of subjects: 800
Study 2863224 — intervention group
Group type: EXPERIMENTAL
Intervention: H1-antagonist clemastine
Number of subjects: 800
Study 31409286 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message-based intervention promoting breastfeeding and appropriate complementary feeding (18 messages over 4 months)
Number of subjects: 80
Study 27893535 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU)
Number of subjects: 379
Study 27893535 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine (GEM)
Number of subjects: 379
Study 26540732 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous high‐dose methylprednisolone treatment
Number of subjects: 48
Study 26540732 — intervention group
Group type: COMPARATOR
Intervention: Oral high‐dose methylprednisolone treatment
Number of subjects: 48
Study 24629554 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported activity (MVPA-SR) in KAM
Number of subjects: 0
Study 24629554 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported activity (MVPA-SR) in KIO
Number of subjects: 0
Study 24629554 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometry (MVPA-A) in KAM
Number of subjects: 0
Study 24629554 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometry (MVPA-A) in KIO
Number of subjects: 0